Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders

References

• Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer 2008;8:473–80.
   PubMed Web of Science ®Google Scholar
• Gelpi A, Gilbertson A, Tucker JD. Magic bullet: Paul Ehrlich, Salvarsan and the birth of venereology. Sex Transm Infect 2015;91:68–9.
   Web of Science ®Google Scholar
• Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. International Natural Product Sciences Taskforce, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov 2021;20:200–16.
   PubMed Web of Science ®Google Scholar
• Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 2004;9:641–51.
   PubMed Web of Science ®Google Scholar
• Meunier B. Hybrid molecules with a dual mode of action: dream or reality? Acc Chem Res 2008;41:69–77.
   PubMed Web of Science ®Google Scholar
• Gediya LK, Njar VCO. Promise and challenges in drug discovery and development of hybrid anticancer drugs. Expert Opin Drug Discov 2009;4:1099–111.
   PubMed Web of Science ®Google Scholar
• Pedrosa MD, da Cruz RMD, Viana JD. Hybrid compounds as direct multitarget ligands: a review. Curr Top Med Chem 2017;17:1044–79.
   PubMed Web of Science ®Google Scholar
• Szumilak M, Wiktorowska-Owczarek A, Stanczak A. Hybrid drugs-a strategy for overcoming anticancer drug resistance? Molecules 2021;26:2601.
   PubMed Web of Science ®Google Scholar
• Pirolla NFF, Batista VS, Dias Viegas FP, et al. Alzheimer’s disease: related targets, synthesis of available drugs, bioactive compounds under development and promising results obtained from multi-target approaches. Curr Drug Targets 2021;22:505–38.
   PubMed Web of Science ®Google Scholar
• Malafaia D, Albuquerque HMT, Silva AMS. Amyloid-β and tau aggregation dual-inhibitors: a synthetic and structure-activity relationship focused review. Eur J Med Chem 2021;214:113209.
   PubMed Web of Science ®Google Scholar
• Stępnicki P, Kondej M, Koszła O, et al. Multi-targeted drug design strategies for the treatment of schizophrenia. Expert Opin Drug Discov 2021;16:101–14.
   PubMed Web of Science ®Google Scholar
• Wetzel C, Lonneman M, Wu C. Polypharmacological drug actions of recently FDA approved antibiotics. Eur J Med Chem 2021;209:112931.
   PubMed Web of Science ®Google Scholar
• Ma Y, Frutos-Beltrán E, Kang D, et al. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chem Soc Rev 2021;50:4514–40.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023–32.
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Emerging role of carbonic anhydrase inhibitors. Clin Sci 2021;35:1233–49.
   Google Scholar
• Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev 2020;40:2485–565.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.
   PubMed Web of Science ®Google Scholar
• Mincione F, Nocentini A, Supuran CT. Advances in the discovery of novel agents for the treatment of glaucoma. Expert Opin Drug Discov 2021.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. Expert Opin Ther Pat 2018;28:713–21.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat 2013;23:725–35.
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs 2018;27:963–70.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. J Exp Pharmacol 2020;12:603–17.
   PubMedGoogle Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother 2016;16:961–8.
   PubMed Web of Science ®Google Scholar
• Bulli I, Dettori I, Coppi E, et al. Role of carbonic anhydrase in cerebral ischemia and carbonic anhydrase inhibitors as putative protective agents. Int J Mol Sci 2021;22:5029.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Capasso C. Antibacterial carbonic anhydrase inhibitors: an update on the recent literature. Expert Opin Ther Pat 2020;30:963–82.
   PubMed Web of Science ®Google Scholar
• Vermelho AB, Rodrigues GC, Supuran CT. Why hasn’t there been more progress in new Chagas disease drug discovery? Expert Opin Drug Discov 2020;15:145–58.
   PubMed Web of Science ®Google Scholar
• Kaur J, Cao X, Abutaleb NS, et al. Optimization of acetazolamide-based scaffold as potent inhibitors of vancomycin-resistant Enterococcus. J Med Chem 2020;63:9540–62.
   PubMed Web of Science ®Google Scholar
• Hewitt CS, Abutaleb NS, Elhassanny AEM, et al. Structure-activity relationship studies of acetazolamide-based carbonic anhydrase inhibitors with activity against Neisseria gonorrhoeae. ACS Infect Dis. 2021.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Capasso C. A highlight on the inhibition of fungal carbonic anhydrases as drug targets for the antifungal armamentarium. Int J Mol Sci 2021;22:4324.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases and metabolism. Metabolites 2018;8:25.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov 2020;15:671–86.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Angeli A, Carta F, et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem 2021;36:561–80.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Carbonic anhydrase inhibitor – NO donor hybrids and their pharmacologic applications. In Bonavida B, Morbidelli L, eds. Therapeutic applications of nitric oxide in cancer and inflammatory-related disorders. Amsterdam (The Netherlands): Elsevier; 2019: 229–242.
   Google Scholar
• Weinreb RN, Liebmann JM, Martin KR, et al. Latanoprostene Bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings. J Glaucoma 2018;27:7–15.
   PubMed Web of Science ®Google Scholar
• Eysteinsson T, Gudmundsdottir H, Hardarson AO, et al. Carbonic anhydrase inhibitors of different structures dilate pre-contracted porcine retinal arteries. Int J Mol Sci 2019;20:467.
   Web of Science ®Google Scholar
• Steele RM, Benedini F, Biondi S, et al. Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma. Bioorg Med Chem Lett 2009;19:6565–70.
   PubMed Web of Science ®Google Scholar
• Mincione F, Benedini F, Biondi S, et al. Synthesis and crystallographic analysis of new sulphonamides incorporating NO-donating moieties with potent antiglaucoma action. Bioorg Med Chem Lett 2011;21:3216–21.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Mincione F, Somma T, et al. A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzyme Inhib Med Chem 2012;27:138–47.
   PubMed Web of Science ®Google Scholar
• Chegaev K, Lazzarato L, Tamboli Y, et al. Furazan and furoxan sulphonamides are strong α-carbonic anhydrase inhibitors and potential antiglaucoma agents. Bioorg Med Chem 2014;22:3913–21.
   PubMed Web of Science ®Google Scholar
• Angeli A, Supuran CT. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018). Expert Opin Ther Pat 2019;29:793–803.
   PubMed Web of Science ®Google Scholar
• Long DD, Frieman B, Hegde SS, et al. A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma. Bioorg Med Chem Lett 2013;23:939–43.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Ceruso M, Bua S, et al. Discovery of β-adrenergic receptors blocker-carbonic anhydrase inhibitor hybrids for multitargeted antiglaucoma therapy. J Med Chem 2018;61:5380–94.
   PubMed Web of Science ®Google Scholar
• Papapetropoulos A, Foresti R, Ferdinandy P. Pharmacology of the ‘gasotransmitters’ NO, CO and H2S: translational opportunities. Br J Pharmacol 2015;172:1395–6.
   PubMed Web of Science ®Google Scholar
• Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 1968;61:748–55.
   PubMed Web of Science ®Google Scholar
• Willis D, Moore AR, Willoughby DA. Heme oxygenase isoform expression in cellular and antibody-mediated models of acute inflammation in the rat. J Pathol 2000;190:627–34.
   PubMed Web of Science ®Google Scholar
• Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. Nat Rev Drug Discov 2010;9:728–43.
   PubMed Web of Science ®Google Scholar
• Ott I, Kircher B, Dembinski R, Gust R. Alkyne hexacarbonyl dicobalt complexes in medicinal chemistry and drug development. Expert Opin Ther Pat 2008;18:327–37.
   Web of Science ®Google Scholar
• Berrino E, Milazzo L, Micheli L, et al. Synthesis and evaluation of carbonic anhydrase inhibitors with carbon monoxide releasing properties for the management of rheumatoid arthritis. J Med Chem 2019;62:7233–49.
   PubMed Web of Science ®Google Scholar
• Berrino E, Carradori S, Angeli A, et al. Dual carbonic anhydrase IX/XII inhibitors and carbon monoxide releasing molecules modulate LPS-mediated inflammation in mouse macrophages. Antioxidants 2021;10:56.
   Web of Science ®Google Scholar
• Gallorini M, Berardi AC, Ricci A, et al. Dual acting carbon monoxide releasing molecules and carbonic anhydrase inhibitors differentially modulate inflammation in human tenocytes. Biomedicines 2021;9:141.
   PubMed Web of Science ®Google Scholar
• Bua S, Di Cesare Mannelli L, Vullo D, et al. Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis. J Med Chem 2017;60:1159–70.
   PubMed Web of Science ®Google Scholar
• Bua S, Lucarini L, Micheli L, et al. Bioisosteric development of multitarget nonsteroidal anti-inflammatory drug-carbonic anhydrases inhibitor hybrids for the management of rheumatoid arthritis. J Med Chem 2020;63:2325–42.
   PubMed Web of Science ®Google Scholar
• Menicatti M, Pallecchi M, Bua S, et al. Resolution of co-eluting isomers of anti-inflammatory drugs conjugated to carbonic anhydrase inhibitors from plasma in liquid chromatography by energy-resolved tandem mass spectrometry. J Enzyme Inhib Med Chem 2018;33:671–9.
   PubMed Web of Science ®Google Scholar
• Akgul O, Di Cesare Mannelli L, Vullo D, et al. Discovery of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the management of rheumatoid arthritis. J Med Chem 2018;61:4961–77.
   PubMed Web of Science ®Google Scholar
• Micheli L, Bozdag M, Akgul O, et al. Pain relieving effect of-NSAIDs-CAIs hybrid molecules: systemic and intra-articular treatments against rheumatoid arthritis. Int J Mol Sci 2019;20:1923.
   Web of Science ®Google Scholar
• Lucarini L, Durante M, Sgambellone S, et al. Effects of new NSAID-CAI hybrid compounds in inflammation and lung fibrosis. Biomolecules 2020;10:1307.
   Web of Science ®Google Scholar
• Margheri F, Ceruso M, Carta F, et al. Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium. J Enzyme Inhib Med Chem 2016;31:60–3.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Chia S, Bedard PL, et al. A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am J Clin Oncol 2020;43:484–90.
   PubMed Web of Science ®Google Scholar
• Krall N, Pretto F, Decurtins W, et al. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl 2014; 53:4231–5.
   PubMed Web of Science ®Google Scholar
• Cazzamalli S, Ziffels B, Widmayer F, et al. Enhanced therapeutic activity of non-internalizing small-molecule-drug conjugates targeting carbonic anhydrase IX in combination with targeted interleukin-2. Clin Cancer Res 2018; 24:3656–67.
   PubMed Web of Science ®Google Scholar
• Cazzamalli S, Dal Corso A, Widmayer F, Neri D. Chemically defined antibody- and small molecule-drug conjugates for in vivo tumor targeting applications: a comparative analysis. J Am Chem Soc 2018;140:1617–21.
   PubMed Web of Science ®Google Scholar
• Marks IS, Gardeen SS, Kurdziel SJ, et al. Development of a small molecule tubulysin B conjugate for treatment of carbonic anhydrase IX receptor expressing cancers. Mol Pharm 2018;15:2289–96.
   PubMedGoogle Scholar
• Buller F, Steiner M, Frey K, et al. Selection of carbonic anhydrase IX inhibitors from one million DNA-encoded compounds. ACS Chem Biol 2011;6:336–44.
   PubMed Web of Science ®Google Scholar
• An R, Lin B, Zhao S, et al. Discovery of novel artemisinin-sulphonamidehybrids as potential carbonicanhydrase IX inhibitors with improved antiproliferative activities. Bioorg Chem 2020;104:104347.
   PubMed Web of Science ®Google Scholar
• Yu H, Hou Z, Tian Y, et al. Design, synthesis, cytotoxicity and mechanism of novel dihydroartemisinin-coumarin hybrids as potential anti-cancer agents. Eur J Med Chem 2018;151:434–49.
   PubMed Web of Science ®Google Scholar
• Tian Y, Liang Z, Xu H, et al. Design, synthesis and cytotoxicity of novel dihydroartemisinin-coumarin hybrids via click chemistry. Molecules 2016;21:758.
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057–62.
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Pochet L, et al. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem 2010;53:335–44.
   PubMed Web of Science ®Google Scholar
• Peerzada MN, Hamel E, Bai R, et al. Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development. Pharmacol Ther 2021;225:107860.
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu Z, Xia S, et al. Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors. Eur J Med Chem 2021;216:113300.
   PubMed Web of Science ®Google Scholar
• Elzahhar PA, Abd El Wahab SM, Elagawany M, et al. Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting cyclooxygenase-2,15-lipoxygenase and tumor-associated carbonic anhydrases. Eur J Med Chem 2020;200:112439.
   PubMed Web of Science ®Google Scholar
• Berrino E, Angeli A, Zhdanov DD, et al. Azidothymidine “clicked” into 1,2,3-triazoles: first report on carbonic anhydrase-telomerase dual-hybrid inhibitors. J Med Chem 2020;63:7392–409.
   PubMed Web of Science ®Google Scholar
• Teodori E, Braconi L, Bua S, et al. Dual P-glycoprotein and CA XII inhibitors: a new strategy to reverse the P-gp mediated multidrug resistance (MDR) in cancer cells. Molecules 2020;25:1748.
   PubMed Web of Science ®Google Scholar
• Krasavin M, Sharonova T, Sharoyko V, et al. Combining carbonic anhydrase and thioredoxin reductase inhibitory motifs within a single molecule dramatically increases its cytotoxicity. J Enzyme Inhib Med Chem 2020;35:665–71.
   PubMed Web of Science ®Google Scholar
• Krasavin M, Žalubovskis R, Grandāne A, et al. Sulphocoumarins as dual inhibitors of human carbonic anhydrase isoforms IX/XII and of human thioredoxin reductase. J Enzyme Inhib Med Chem 2020;35:506–10.
   PubMed Web of Science ®Google Scholar
• Innocenti A, Gülçin I, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett 2010;20:5050–3.
   PubMed Web of Science ®Google Scholar
• Briganti F, Pierattelli R, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. Eur J Med Chem 1996;31:1001–10.
   Web of Science ®Google Scholar
• Berrino E, Michelet B, Martin-Mingot A, et al. Modulating the efficacy of carbonic anhydrase inhibitors through fluorine substitution. Angew Chem Int Ed Engl 2021.
   PubMedGoogle Scholar